{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:57:44Z","timestamp":1793026664368,"version":"4.5.0"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Diagnosing Dementia with Lewy Bodies (DLB) remains a challenge in clinical practice. The use of\n                      <jats:sup>123<\/jats:sup>\n                      I-ioflupane (DaTscan\n                      <jats:sup>\u2122<\/jats:sup>\n                      ) SPECT imaging, which detects reduced dopamine transporter (DAT) uptake\u2014a key biomarker in DLB diagnosis\u2014could improve diagnostic accuracy. However, DAT imaging is underutilized despite its potential, contributing to delays and suboptimal patient management.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review evaluates DLB diagnostic practices and challenges faced within the U.S. by synthesizing information from current literature, consensus guidelines, expert opinions, and recent updates on DaTscan FDA filings. It contrasts DAT SPECT with alternative biomarkers, provides recommendations for when DAT SPECT imaging may be indicated and discusses the potential of emerging biomarkers in enhancing diagnostic approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The radiopharmaceutical\n                      <jats:sup>123<\/jats:sup>\n                      I-ioflupane for SPECT imaging was initially approved in Europe (2000) and later in the US (2011) for Parkinsonism\/Essential Tremor. Its application was extended in 2022 to include the diagnosis of DLB. DaTscan\u2019s diagnostic efficacy for DLB, with its sensitivity, specificity, and predictive values, confirms its clinical utility. However, US implementation faces challenges such as insurance barriers, costs, access issues, and regional availability disparities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:sup>123<\/jats:sup>\n                      I-ioflupane SPECT Imaging is indicated for DLB diagnosis and differential diagnosis of Alzheimer\u2019s Disease, particularly in uncertain cases. Addressing diagnostic obstacles and enhancing physician-patient education could improve and expedite DLB diagnosis. Collaborative efforts among neurologists, geriatric psychiatrists, psychologists, and memory clinic staff are key to increasing diagnostic accuracy and care in DLB management.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2024.1395413","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T12:20:53Z","timestamp":1713788453000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Practical use of DAT SPECT imaging in diagnosing dementia with Lewy bodies: a US perspective of current guidelines and future directions"],"prefix":"10.3389","volume":"15","author":[{"given":"Deirdre M.","family":"O\u2019Shea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Arkhipenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Galasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer G.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulfiqar Haider","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Petrides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon B.","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Galvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-020-02255-2","article-title":"Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-Centre study","volume":"141","author":"Attems","year":"2021","journal-title":"Acta Neuropathol"},{"key":"ref4","year":"2023"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1017\/S0033291713000494","article-title":"The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies","volume":"44","author":"Jones","year":"2014","journal-title":"Psychol Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1176\/jnp.13.3.374","article-title":"Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease","volume":"13","author":"Aarsland","year":"2001","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000327360","article-title":"Prevalence and pathology of dementia with Lewy bodies in the oldest old: a comparison with other dementing disorders","volume":"31","author":"Jellinger","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e3257","DOI":"10.1212\/WNL.0000000000010943","article-title":"\u03b2-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies","volume":"95","author":"Ferreira","year":"2020","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease","volume":"51","author":"Gibb","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1212\/01.wnl.0000204179.88955.fa","article-title":"\u03b1-Synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals","volume":"66","author":"Klos","year":"2006","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1046\/j.0305-1846.2001.00342.x","article-title":"\u03b1-Synuclein pathology is highly dependent on the case selection","volume":"27","author":"Parkkinen","year":"2001","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","article-title":"Cognitive effects of Lewy body pathology in clinically unimpaired individuals","volume":"29","author":"Palmqvist","year":"2023","journal-title":"Nat Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13195-015-0128-z","article-title":"Comprehensive treatment of dementia with Lewy bodies","volume":"7","author":"Boot","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","article-title":"Research criteria for the diagnosis of prodromal dementia with Lewy bodies","volume":"94","author":"McKeith","year":"2020","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.dadm.2015.05.004","article-title":"Improving the clinical detection of Lewy body dementia with the Lewy body composite risk score","volume":"1","author":"Galvin","year":"2015","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/jnnp-2017-316844","article-title":"Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis","volume":"89","author":"Rizzo","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.parkreldis.2010.03.007","article-title":"Lewy body dementia: the caregiver experience of clinical care","volume":"16","author":"Galvin","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/gps.4609","article-title":"Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study","volume":"32","author":"Thomas","year":"2017","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2174\/1570159X13666141204221238","article-title":"Recent progress of imaging agents for Parkinson\u2019s disease","volume":"12","author":"Wu","year":"2014","journal-title":"Curr Neuropharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00259-020-04817-8","article-title":"EANM practice guideline\/SNMMI procedure standard for dopaminergic imaging in parkinsonian syndromes 1.0","volume":"47","author":"Morbelli","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1192\/bjp.bp.114.148643","article-title":"Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study","volume":"206","author":"Walker","year":"2015","journal-title":"Br J Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/MNM.0b013e328343d4ec","article-title":"Impact of 123I-FP-CIT (DaTSCAN) SPECT on the diagnosis and management of patients with dementia with Lewy bodies: a retrospective study","volume":"32","author":"Kemp","year":"2011","journal-title":"Nucl Med Commun"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1007\/s00259-019-04480-8","article-title":"Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: an updated systematic review and Bayesian latent class model meta-analysis","volume":"47","author":"Nihashi","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e005122","DOI":"10.1136\/bmjopen-2014-005122","article-title":"Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials","volume":"4","author":"O\u2019Brien","year":"2014","journal-title":"BMJ Open"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41531-021-00185-8","article-title":"Clinical utility of DaTscan in patients with suspected parkinsonian syndrome: a systematic review and meta-analysis. Npj","volume":"7","author":"Bega","year":"2021","journal-title":"Parkinson's Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40336-020-00386-w","article-title":"Dopamine transporter imaging in neurodegenerative movement disorders: PET vs","volume":"8","author":"Kerstens","year":"2020","journal-title":"SPECT Clin Translat Imag"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s13139-022-00748-4","article-title":"Prospective F-18 FDOPA PET imaging study in human PD","volume":"56","author":"Dhawan","year":"2022","journal-title":"Nucl Med Mol Imaging"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"101441","DOI":"10.1016\/j.disamonth.2022.101441","article-title":"Recent advances in Lewy body dementia: a comprehensive review","volume":"69","author":"Prasad","year":"2023","journal-title":"Dis Mon"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/14728214.2023.2244425","article-title":"Emerging drugs for dementia with Lewy bodies: a review of phase II & III trials","volume":"28","author":"Tolea","year":"2023","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","article-title":"\u03b1-Synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"S221","DOI":"10.1016\/S1353-8020(08)70005-1","article-title":"Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology","volume":"13","author":"Tsuboi","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00702-017-1821-9","article-title":"Dementia with Lewy bodies and Parkinson\u2019s disease-dementia: current concepts and controversies","volume":"125","author":"Jellinger","year":"2018","journal-title":"J Neural Transm"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1212\/CON.0000000000000309","article-title":"Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia","volume":"22","author":"Gomperts","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1212\/WNL.62.2.181","article-title":"DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging","volume":"62","author":"Ferman","year":"2004","journal-title":"Neurology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/ene.15783","article-title":"Clinical symptoms in mild cognitive impairment with Lewy bodies: frequency, time of onset, and discriminant ability","volume":"30","author":"Donaghy","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"15333175221106901","DOI":"10.1177\/15333175221106901","article-title":"The cognitive and language profile of dementia with Lewy bodies","volume":"37","author":"Macoir","year":"2022","journal-title":"Am J Alzheimers Dis Other Dement"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/23279095.2023.2247112","article-title":"Different language profiles on neuropsychological tests in dementia with Lewy bodies and Alzheimer\u2019s disease","author":"Vogel","year":"2023","journal-title":"Appl Neuropsychol Adult"},{"key":"ref38","first-page":"553","article-title":"Dementia with Lewy bodies","volume-title":"Primer on the autonomic nervous system","author":"Leys","year":"2022"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11065-021-09502-7","article-title":"Meta-analysis of cognition in Parkinson\u2019s disease mild cognitive impairment and dementia progression","volume":"32","author":"Wallace","year":"2021","journal-title":"Neuropsychol Rev"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/arclin\/acx085","article-title":"Cognitive and neuropsychiatric features in Parkinson's and Lewy body dementias","volume":"32","author":"Fields","year":"2017","journal-title":"Arch Clin Neuropsychol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fneur.2018.00123","article-title":"Parkinson\u2019s disease dementia and dementia with Lewy bodies have similar neuropsychological profiles","volume":"9","author":"Aldridge","year":"2018","journal-title":"Front Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1212\/WNL.53.5.902","article-title":"Report of the second dementia with Lewy body international workshop: diagnosis and treatment","volume":"53","author":"McKeith","year":"1999","journal-title":"Neurology"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1212\/WNL.0000000000003512","article-title":"Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB","volume":"88","author":"Thomas","year":"2017","journal-title":"Neurology"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00234-016-1773-z","article-title":"Diagnostic imaging of dementia with Lewy bodies by susceptibility-weighted imaging of nigrosomes versus striatal dopamine transporter single-photon emission computed tomography: a retrospective observational study","volume":"59","author":"Kamagata","year":"2017","journal-title":"Neuroradiology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/ana.24717","article-title":"123I-2\u03b2-carbomethoxy-3\u03b2-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and 123I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: a comparative study","volume":"80","author":"Tiraboschi","year":"2016","journal-title":"Ann Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e1648","DOI":"10.1212\/WNL.0000000000200110","article-title":"Autopsy validation of the diagnostic accuracy of 123I-metaiodobenzylguanidine myocardial scintigraphy for Lewy body disease","volume":"98","author":"Matsubara","year":"2022","journal-title":"Neurology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"101745","DOI":"10.1016\/j.smrv.2023.101745","article-title":"Quantification of REM sleep without atonia: a review of study methods and meta-analysis of their performance for the diagnosis of RBD","volume":"68","author":"Puligheddu","year":"2023","journal-title":"Sleep Med Rev"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/brain\/aww005","article-title":"MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases","volume":"139","author":"Harper","year":"2016","journal-title":"Brain"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2967\/jnumed.109.065870","article-title":"The 18F-FDG PET cingulate island sign and comparison to 123I-\u03b2-CIT SPECT for diagnosis of dementia with Lewy bodies","volume":"50","author":"Lim","year":"2009","journal-title":"J Nucl Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3390\/diagnostics10090616","article-title":"The role of EEG in the diagnosis, prognosis and clinical correlations of dementia with Lewy bodies\u2014a systematic review","volume":"10","author":"Law","year":"2020","journal-title":"Diagnostics"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1212\/WNL.0000000000000734","article-title":"Dementia with Lewy bodies: basis of cingulate island sign","volume":"83","author":"Graff-Radford","year":"2014","journal-title":"Neurology"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/WAD.0000000000000414","article-title":"Biomarker use for dementia with Lewy body diagnosis: survey of US experts","volume":"35","author":"Armstrong","year":"2021","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mdc3.12383","article-title":"The case for antipsychotics in dementia with Lewy bodies","volume":"4","author":"Armstrong","year":"2017","journal-title":"Mov Dis Clin Pract"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/bmj.305.6855.673","article-title":"Neuroleptic sensitivity in patients with senile dementia of Lewy body type","volume":"305","author":"McKeith","year":"1992","journal-title":"Br Med J"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40266-018-00636-7","article-title":"Pharmacological management of dementia with Lewy bodies","volume":"36","author":"Hershey","year":"2019","journal-title":"Drugs Aging"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/0891988716656083","article-title":"Revisiting DLB diagnosis: a consideration of prodromal DLB and of the diagnostic overlap with Alzheimer disease","volume":"29","author":"McKeith","year":"2016","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/alzrt274","article-title":"The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis","volume":"6","author":"Donaghy","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/13554790490892239","article-title":"Posterior cortical atrophy: a review of the literature","volume":"10","author":"Caine","year":"2004","journal-title":"Neurocase"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jalz.2017.01.014","article-title":"Consensus classification of posterior cortical atrophy","volume":"13","author":"Crutch","year":"2017","journal-title":"Alzheimers Dement"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/WAD.0b013e3181c72b5d","article-title":"Lewy body dementia: caregiver burden and unmet needs","volume":"24","author":"Galvin","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","article-title":"Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study","volume":"6","author":"McKeith","year":"2007","journal-title":"Lancet Neurol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2967\/jnumed.111.100784","article-title":"SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0","volume":"53","author":"Djang","year":"2012","journal-title":"J Nucl Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.2967\/jnumed.116.189266","article-title":"Diagnostic performance of the visual Reading of (123)I-Ioflupane SPECT images with or without quantification in patients with movement disorders or dementia","volume":"58","author":"Booij","year":"2017","journal-title":"J Nucl Med"},{"key":"ref65","unstructured":""},{"key":"ref66","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3390\/tomography7040081","article-title":"Practical application of DaTQUANT with optimal threshold for diagnostic accuracy of dopamine transporter SPECT","volume":"7","author":"Neill","year":"2021","journal-title":"Tomography"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","article-title":"Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F] FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0","volume":"49","author":"Lopci","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref68","volume-title":"A comparison of dopamine active transporter (DAT) quantification applications (HERMES BRASS v2. 5 and GE DaTQUANT v1. 01)","author":"Rai","year":"2018"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00259-020-05168-0","article-title":"A diagnostic strategy for parkinsonian syndromes using quantitative indices of DAT SPECT and MIBG scintigraphy: an investigation using the classification and regression tree analysis","volume":"48","author":"Iwabuchi","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"120713","DOI":"10.1016\/j.jns.2023.120713","article-title":"Striatal dopamine transporter binding differs between dementia with Lewy bodies and Parkinson\u2019s disease with dementia","volume":"451","author":"Ishizawa","year":"2023","journal-title":"J Neurol Sci"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/14737175.2017.1256205","article-title":"Clinical utility of DaTscan\u2122 imaging in the evaluation of patients with parkinsonism: a US perspective","volume":"17","author":"Isaacson","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/jnnp-2018-320157","article-title":"Clinical implications of early caudate dysfunction in Parkinson\u2019s disease","volume":"90","author":"Pasquini","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/psyg.13025","article-title":"Association between longitudinal changes in striatal dopamine transporter uptake and clinical features of dementia with Lewy bodies","volume":"23","author":"Yamamoto","year":"2023","journal-title":"Psychogeriatrics"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s00259-016-3312-x","article-title":"[123] FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies","volume":"43","author":"Van der Zande","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1002\/gps.5839","article-title":"Disease progression in dementia with Lewy bodies: a longitudinal study on clinical symptoms, quality of life and functional impairment","volume":"37","author":"van de Beek","year":"2022","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1017\/S0033291718000995","article-title":"Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies","volume":"49","author":"Thomas","year":"2019","journal-title":"Psychol Med"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/mds.27361","article-title":"Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort","volume":"33","author":"Simuni","year":"2018","journal-title":"Mov Disord"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/jnnp-2017-316213","article-title":"Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson\u2019s disease: the PPMI cohort","volume":"89","author":"Simuni","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00259-023-06171-x","article-title":"A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I] I-FP-CIT SPECT in routine practice","author":"Chahid","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1136\/jnnp.2006.111666","article-title":"Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer\u2019s disease from dementia with Lewy bodies","volume":"78","author":"Taylor","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s00259-007-0621-0","article-title":"Dopamine transporter imaging with [123 I] FP-CIT SPECT: potential effects of drugs","volume":"35","author":"Booij","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.53.9.2003","article-title":"Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies","volume":"53","author":"Gomez-Isla","year":"1999","journal-title":"Neurology"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s007020050176","article-title":"Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology","volume":"106","author":"Lippa","year":"1999","journal-title":"J Neural Transm"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"e1855","DOI":"10.1212\/WNL.0000000000011699","article-title":"Cognitive profile and markers of Alzheimer disease\u2013type pathology in patients with Lewy body dementias","volume":"96","author":"Howard","year":"2021","journal-title":"Neurology"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1212\/WNL.0000000000008818","article-title":"\u03b2-Amyloid PET and neuropathology in dementia with Lewy bodies","volume":"94","author":"Kantarci","year":"2020","journal-title":"Neurology"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4172\/2161-0460.1000444","article-title":"The contribution of tau, amyloid-beta and alpha-synuclein pathology to dementia in Lewy body disorders","volume":"8","author":"Irwin","year":"2018","journal-title":"J Alzheimer's Dis Parkinsonism"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1093\/brain\/awab218","article-title":"Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks","volume":"144","author":"Schumacher","year":"2021","journal-title":"Brain"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/alzrt109","article-title":"Examining the mechanisms that link \u03b2-amyloid and \u03b1-synuclein pathologies","volume":"4","author":"Marsh","year":"2012","journal-title":"Alzheimers Res Ther"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/alz.12814","article-title":"Dementia with Lewy bodies: impact of co-pathologies and implications for clinical trial design","volume":"19","author":"Toledo","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/ane.13028","article-title":"Lewy body pathology in Alzheimer's disease: a clinicopathological prospective study","volume":"139","author":"Savica","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1007\/s00259-023-06154-y","article-title":"The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review","volume":"50","author":"Jreige","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1212\/WNL.0b013e3181ca017d","article-title":"Effect of cognitive fluctuation on neuropsychological performance in aging and dementia","volume":"74","author":"Escandon","year":"2010","journal-title":"Neurology"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1177\/0898264315611669","article-title":"Daily fluctuations in everyday cognition: is it meaningful?","volume":"28","author":"Gamaldo","year":"2016","journal-title":"J Aging Health"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jagp.2013.01.072","article-title":"The dementia cognitive fluctuation scale, a new psychometric test for clinicians to identify cognitive fluctuations in people with dementia","volume":"22","author":"Lee","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/RLU.0000000000001696","article-title":"Utility of follow-up dopamine transporter SPECT with 123I-FP-CIT in the diagnostic workup of patients with clinically uncertain parkinsonian syndrome","volume":"42","author":"Apostolova","year":"2017","journal-title":"Clin Nucl Med"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1002\/ana.21602","article-title":"Biomarkers for Parkison's disease: tools to assess Parkinson's disease onset and progression","volume":"64","author":"Marek","year":"2008","journal-title":"Ann Neurol"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000488780","article-title":"Estimating the evolution of disease in the Parkinson\u2019s progression markers initiative","volume":"18","author":"Iddi","year":"2018","journal-title":"Neurodegener Dis"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/mds.27330","article-title":"Initial cognitive changes in Parkinson's disease","volume":"33","author":"Weintraub","year":"2018","journal-title":"Mov Disord"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/RLU.0000000000001815","article-title":"ACR\u2013ACNM practice parameter for the performance of dopamine transporter (DAT) single photon emission computed tomography (SPECT) imaging for movement disorders","volume":"42","author":"Subramaniam","year":"2017","journal-title":"Clin Nucl Med"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1192\/bjp.2020.234","article-title":"Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies","volume":"218","author":"Roberts","year":"2021","journal-title":"Br J Psychiatry"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"e2685","DOI":"10.1212\/WNL.0000000000012024","article-title":"Progression to dementia in mild cognitive impairment with Lewy bodies or Alzheimer disease","volume":"96","author":"Hamilton","year":"2021","journal-title":"Neurology"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"e1196","DOI":"10.1212\/WNL.0000000000207621","article-title":"Serial nigrostriatal dopaminergic imaging in mild cognitive impairment with Lewy bodies, Alzheimer disease, and age-matched controls","volume":"101","author":"Durcan","year":"2023","journal-title":"Neurology"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11481-019-09835-4","article-title":"Ultrasensitive detection of aggregated \u03b1-synuclein in glial cells, human cerebrospinal fluid, and brain tissue using the RT-QuIC assay: new high-throughput neuroimmune biomarker assay for parkinsonian disorders","volume":"14","author":"Manne","year":"2019","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","article-title":"Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies","volume":"140","author":"Rossi","year":"2020","journal-title":"Acta Neuropathol"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson's progression markers initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"132","DOI":"10.20517\/2347-8659.2020.01","article-title":"Assessment of cerebrospinal fluid \u03b1-synuclein as a potential biomarker in Parkinson\u2019s disease and synucleinopathies","volume":"2020","author":"Chalatsa","year":"2020","journal-title":"Neuroimmunol Neuroinflam"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1212\/WNL.0000000000004146","article-title":"A new potential biomarker for dementia with Lewy bodies: skin nerve \u03b1-synuclein deposits","volume":"89","author":"Donadio","year":"2017","journal-title":"Neurology"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"14246","DOI":"10.1038\/s41598-018-32588-8","article-title":"Skin \u03b1-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study","volume":"8","author":"Donadio","year":"2018","journal-title":"Sci Rep"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13311-023-01379-z","article-title":"Fluid and biopsy based biomarkers in Parkinson\u2019s disease","author":"Coughlin","year":"2023","journal-title":"Neurotherapeutics"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2217\/bmm-2021-0646","article-title":"Synuclein-one study: skin biopsy detection of phosphorylated \u03b1-synuclein for diagnosis of synucleinopathies","volume":"16","author":"Gibbons","year":"2022","journal-title":"Biomark Med"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1474-4422(23)00456-8","article-title":"Criteria for a biological definition of neuronal \u03b1-synuclein disease\u2014a major conceptual step forward","volume":"23","author":"Jack","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/10408363.2019.1711359","article-title":"Methods for detecting toxic \u03b1-synuclein species as a biomarker for Parkinson\u2019s disease","volume":"57","author":"O\u2019Hara","year":"2020","journal-title":"Crit Rev Clin Lab Sci"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1395413\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T12:20:59Z","timestamp":1713788459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1395413\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":112,"alternative-id":["10.3389\/fneur.2024.1395413"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1395413","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"article-number":"1395413"}}